^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    1d
    Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML (clinicaltrials.gov)
    P1/2, N=29, Recruiting, The First Affiliated Hospital of Soochow University
    New P1/2 trial
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    1d
    ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine – a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT) (ACTRN12626000278336)
    P=N/A, N=100, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    1d
    A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2/3, N=216, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=80 --> 216 | Initiation date: Dec 2025 --> Mar 2026
    Enrollment change • Trial initiation date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • BL-M11D1
    2d
    VICEROY: A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine
    3d
    MC2TCR: MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Erasmus Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    azacitidine
    3d
    BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden
    |
    Chr t(15;17)
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine
    4d
    A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE. (PubMed, Int J Hematol)
    Results from the Japanese population enrolled in AGILE are aligned with those of the overall study. The efficacy of ivosidenib plus azacitidine in Japanese mIDH1 AML patients enrolled in AGILE who were ineligible for intensive chemotherapy appears to be consistent with the overall study population.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Tibsovo (ivosidenib)
    5d
    AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration (clinicaltrials.gov)
    P=N/A, N=80, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    5d
    Daratumumab-based salvage therapy enables umbilical cord blood transplantation in multiline refractory, elderly T-lymphoblastic lymphoma: a case report. (PubMed, Front Immunol)
    We report a case of a 60-year-old man with multi-refractory T-LBL exhibiting a partial response to hyper-CVAD followed by progression on venetoclax plus azacitidine. This patient achieved complete remission after a single cycle of DMPD salvage therapy comprising daratumumab, liposomal mitoxantrone, pegaspargase and dexamethasone...It successfully bridged the patient to double umbilical cord blood transplantation, resulting in full donor chimerism by day +21 and sustained remission despite post-transplant complications. The remarkable efficacy observed in this refractory T-LBL case, contrasting sharply with historical treatment outcomes, suggests that the DMPD regimen may serve as both an immediately actionable and potentially definitive therapeutic approach for elderly patients who are ineligible for hematopoietic stem cell transplantation.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • Darzalex (daratumumab) • dexamethasone • Oncaspar liquid (pegaspargase) • Duoenda (mitoxantrone liposomal)
    7d
    Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD (clinicaltrials.gov)
    P2, N=37, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Aug 2026 --> Oct 2027
    Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    7d
    ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial (clinicaltrials.gov)
    P1/2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | N=12 --> 3 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    azacitidine • sabatolimab (MBG453)
    8d
    Efficacy and safety of Venetoclax combined with Azacitidine in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - a single-center retrospective study. (PubMed, Curr Res Transl Med)
    The early use of VEN-AZA appears to be effective and well tolerated in AML patients with molecular relapse after allo-HSCT, particularly in those carrying CBFβ::MYH11 fusion gene or NPM1 mutation.
    Retrospective data • Journal
    |
    NPM1 (Nucleophosmin 1) • CBFB (Core-Binding Factor Subunit Beta 2)
    |
    NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine